keyword
MENU ▼
Read by QxMD icon Read
search

Medication adverse events

keyword
https://www.readbyqxmd.com/read/29045961/-effects-of-recent-upper-respiratory-tract-infections-on-incidence-of-the-perioperative-respiratory-adverse-events-in-children-a-prospective-cohort-study
#1
C Q Li, D X Wang, T Cheng, X Y Zheng
OBJECTIVE: To investigate the effects of the recent upper respiratory tract infections (URI) on the incidence of perioperative respiratory adverse events in children scheduled to undergo general anesthesia and elective surgery. METHODS: In the study, 232 children undergoing general anesthesia with laryngeal mask airway (LMA) for elective ophthalmic surgeries at Peking University First Hospital, Beijing, China, from Nov. 1, 2015 to May 10, 2016 were enrolled. On the day of the surgery, the parents of the children were preoperatively asked to fill out a questionnaire regarding the baseline characteristics and medical history of the children, including gender, age, height, weight, history of URI within the last 2 weeks before anesthesia, history of premature, long-term passive smoking exposure, habitual sleep snoring, and history of asthma...
October 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/29045288/effects-of-anti-inflammatory-medications-in-patients-with-coronary-artery-disease-a-focus-on-losmapimod
#2
Bradley Tun, William H Frishman
Inflammation plays an integral role in atherogenesis and the pathogenesis of coronary artery disease (CAD). The question remains as to whether targeted inhibition of specific pathways of inflammation will have any clinical benefits in CAD. In this article we will review p38 mitogen-activated protein kinase (p38 MAPK), one of the key sensors of cellular stress that plays an important role in the inflammatory cascade. In addition, we will review losmapimod, a reversible competitive inhibitor of the α and β isoforms of p38 MAPK, and its efficacy when added to standard of care in patients hospitalized with myocardial infarction...
October 17, 2017: Cardiology in Review
https://www.readbyqxmd.com/read/29045285/milrinone-dosing-and-a-culture-of-caution-in-clinical-practice
#3
Luke Yong Zheng Chong, Kumar Satya, Bernard Kim, Robert Berkowitz
Milrinone is an invaluable agent in the treatment of end-stage heart failure patients who are refractory to optimal medical therapy. In addition to its use in acute decompensated heart failure, milrinone can also be employed as a home infusion therapy or a bridge to cardiac transplant. Concerns about its adverse effects, such as an increased risk of arrhythmias and hypotension, often limit the doses of milrinone used in clinical practice. In addition, milrinone is infrequently used or avoided entirely in patients with acute renal failure or end-stage renal disease since the drug is primarily cleared by renal excretion...
October 17, 2017: Cardiology in Review
https://www.readbyqxmd.com/read/29045169/use-of-topical-cannabinomimetic-palmitoylethanolamide-in-ocular-surface-disease-associated-with-antiglaucoma-medications
#4
Antonio Di Zazzo, Gloria Roberti, Alireza Mashaghi, Tulio Batista Abud, Daniela Pavese, Stefano Bonini
PURPOSE: Chronic use of topical hypotensive therapies in glaucoma patients leads to chronic inflammation of the ocular surface, which decreases the success rate of long-term glaucoma management. The aim of this study is to evaluate the effect of topical palmitoylethanolamide (PEA) (Defluxa(©)), a well-known anti-inflammatory and analgesic agent, in suppressing the ocular surface inflammation associated with the use of hypotensive eye drops. METHODS: In a pilot clinical trial, we enrolled 15 glaucomatous patients who received topical PEA (Defluxa) in addition to the current antiglaucoma drugs, while 15 glaucomatous patients did not receive any additional treatment...
November 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29045163/real-world-effectiveness-of-brentuximab-vedotin-versus-physicians-choice-chemotherapy-in-patients-with-relapsed-refractory-hodgkin-lymphoma-following-autologous-stem-cell-transplantation-in-the-united-kingdom-and-germany
#5
Erin A Zagadailov, Shelby Corman, Viktor Chirikov, Courtney Johnson, Cynthia Macahilig, Brian Seal, Mehul R Dalal, Paul J Bröckelmann, Tim Illidge
This retrospective study compared effectiveness of (brentuximab vedotin) BV to other chemotherapies in patients with rrHL following an autologous stem cell transplant (ASCT). Data originated from a medical chart review of patients treated in real-world clinical settings at 50 sites in the United Kingdom and Germany. Inverse probability of treatment weights based on propensity scores were used to adjust for differences in baseline characteristics between treatment groups. Among 312 rrHL patients included, 196 received BV and 116 received physicians' choice chemotherapy...
October 18, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29043496/erlotinib-plus-bevacizumab-phase-ll-study-in-patients-with-advanced-non-small-cell-lung-cancer-jo25567-updated-safety-results
#6
Terufumi Kato, Takashi Seto, Makoto Nishio, Koichi Goto, Noboru Yamamoto, Isamu Okamoto, Liang Tao, Wei Yu, Tarik Khaznadar, Kosei Tajima, Masahiko Shibata, Akihiro Seki, Nobuyuki Yamamoto
INTRODUCTION: The phase II JO25567 study compared the efficacy and safety of erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). OBJECTIVE: Our objective is to provide updated analyses of safety and the assessment of manageability of specific adverse events. METHODS: Patients with stage IIIB/IV or recurrent, non-squamous, EGFR mutation-positive NSCLC were randomized to receive erlotinib plus bevacizumab or erlotinib...
October 17, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29042833/impact-of-a-pharmacist-led-chemotherapy-education-program-on-the-knowledge-of-pediatric-hematology-oncology-nurses
#7
Christine M Fisher, Abby J Kim, Joshua J Elder
OBJECTIVES: Medication errors involving chemotherapy are a serious source of avoidable medical harm that can result in chemotherapy-related adverse drug events. Efforts to reduce errors in the past decade have largely focused on chemotherapy errors at the prescriber level, using computerized or automated technology, but little has been done to ensure chemotherapy is administered accurately at the nursing level. The current study implemented a pharmacist-led, supplemental, institution-specific training program to nursing staff regarding the use of chemotherapy and to address knowledge deficits in newly hired nursing personnel...
September 2017: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/29042752/spotlight-on-perampanel-in-the-management-of-seizures-design-development-and-an-update-on-place-in-therapy
#8
REVIEW
Michele A Faulkner
PURPOSE: Perampanel is a first-in-class antiepileptic medication approved for the treatment of partial (focal) seizures, and as adjunctive treatment for primarily generalized tonic-clonic seizures. The pharmacology, efficacy data, adverse-effect profile, pharmacokinetics and place in therapy are reviewed. SUMMARY: Perampanel is indicated for use in patients with epilepsy who are 12 years of age or older. It is the first medication designed specifically to be a non-competitive antagonist at post-synaptic α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29042367/safety-and-efficacy-of-long-term-treatment-of-chronic-persistent-itp-with-eltrombopag-final-results-of-the-extend-study
#9
Raymond S M Wong, Mansoor N Saleh, Abderrahim Khelif, Abdulgabar Salama, Maria Socorro O Portella, Paul Burgess, James B Bussel
In phase 2/3 trials, eltrombopag treatment for ≤6 months in patients with chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding. The open-label EXTEND study evaluated long-term safety and efficacy of eltrombopag in adults with ITP who had completed a previous eltrombopag study. For the 302 patients enrolled, median duration of eltrombopag treatment was 2.37 years (2 days to 8.76 years). Median platelet counts increased to ≥50×10(9)/L by week 2 and were sustained throughout the treatment period...
October 17, 2017: Blood
https://www.readbyqxmd.com/read/29041910/takotsubo-cardiomyopathy-in-a-patient-with-ileus-a-case-report
#10
Chen-Yu C Guo, Nan-Sung Chou
BACKGROUND: Takotsubo cardiomyopathy (TCM) is a form of stress-induced cardiomyopathy featured by the dilatation of the apex of the left ventricle during systole. Whereas the pathogenesis of this disorder is not well understood, it usually occurs after an emotional or physical stress such as acute asthma, surgery, chemotherapy, and stroke. However, its occurrence in ileus patients is rarely reported. We hereby report probably the first case of TCM after ileus in the literature and discuss its implications...
October 17, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/29039073/a-double-blind-randomized-phase-ii-dose-finding-study-of-olanzapine-10%C3%A2-mg-or-5%C3%A2-mg-for-the-prophylaxis-of-emesis-induced-by-highly-emetogenic-cisplatin-based-chemotherapy
#11
Takako Yanai, Satoru Iwasa, Hironobu Hashimoto, Fumiyoshi Ohyanagi, Tomomi Takiguchi, Koji Takeda, Masahiko Nakao, Hiroshi Sakai, Toshiaki Nakayama, Koichi Minato, Takahiro Arai, Kenichi Suzuki, Yasuhiro Shimada, Kengo Nagashima, Hiroyuki Terakado, Noboru Yamamoto
PURPOSE: The aim of this phase II study was to evaluate the efficacy and safety of two doses (10 and 5 mg) of olanzapine in combination with standard antiemetic treatment (aprepitant, palonosetron, and dexamethasone) for patients receiving highly emetogenic chemotherapy (HEC). METHODS: A multi-institutional, double-blind, randomized phase II, dose-finding study of olanzapine was performed in patients with a malignant solid tumor who were receiving HEC with cisplatin (≥ 50 mg/m(2))...
October 16, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29038880/ct-guided-percutaneous-ethanol-sympatholysis-for-primary-hyperhidrosis
#12
Malcolm Brock, Constantine Frangakis, Christos S Georgiades
PURPOSE: Primary hyperhidrosis (PH) typically involves the craniofacial (CF) or axillary-palmar (AP) region. Our purpose was to determine the safety and efficacy of CT-guided sympatholysis for treating PH. METHODS: In this prospective study, 39 consecutive patients with CF or AP PH were referred for percutaneous sympatholysis. Procedures were performed under CT guidance and minimal sedation. We treated level T2 for CF hyperhidrosis and T2, T3, and T4 for AP hyperhidrosis...
October 16, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29038236/efficacy-of-prophylactic-treatment-for-oxycodone-induced-nausea-and-vomiting-among-patients-with-cancer-pain-point-a-randomized-placebo-controlled-double-blind-trial
#13
Hiroaki Tsukuura, Masayuki Miyazaki, Tatsuya Morita, Mihoko Sugishita, Hiroshi Kato, Yuka Murasaki, Bishal Gyawali, Yoko Kubo, Masahiko Ando, Masashi Kondo, Kiyofumi Yamada, Yoshinori Hasegawa, Yuichi Ando
BACKGROUND: Although opioid-induced nausea and vomiting (OINV) often result in analgesic undertreatment in patients with cancer, no randomized controlled trials have evaluated the efficacy of prophylactic antiemetics for preventing OINV. We conducted this randomized, placebo-controlled, double-blind trial to evaluate the efficacy and safety of prophylactic treatment with prochlorperazine for preventing OINV. MATERIALS AND METHODS: Cancer patients who started to receive oral oxycodone were randomly assigned in a 1:1 ratio to receive either prochlorperazine 5 mg or placebo prophylactically, given three times daily for 5 days...
October 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29037237/the-role-of-national-registries-in-improving-patient-safety-for-hip-and-knee-replacements
#14
Anne Lübbeke, Alan J Silman, Daniel Prieto-Alhambra, Amanda I Adler, Christophe Barea, Andrew J Carr
BACKGROUND: The serious adverse events associated with metal on metal hip replacements have highlighted the importance of improving methods for monitoring surgical implants. The new European Union (EU) device regulation will enforce post-marketing surveillance based on registries among other surveillance tools. Europe has a common regulatory environment, a common market for medical devices, and extensive experience with joint replacement registries. In this context, we elaborate how joint replacement registries, while building on existing structure and data, can better ensure safety and balance risks and benefits...
October 16, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29037046/admet-evaluation-in-drug-discovery-18-reliable-prediction-of-chemical-induced-urinary-tract-toxicity-by-boosting-machine-learning-approaches
#15
Tailong Lei, Huiyong Sun, Yu Kang, Feng Zhu, Hui Liu, Wenfang Zhou, Zhe Wang, Dan Li, Youyong Li, Tingjun Hou
Xenobiotic chemicals and their metabolites are mainly excreted out of our bodies by the The urinary tract is the main organ excreting xenobiotic chemicals and their metabolites through the urine. Chemical-induced urinary tract toxicity is one of the main reasons that cause failure during drug development, and it is a common adverse event for medications, natural supplements and environmental chemicals. Despites its importance, there are only a few in silico models for assessing urinary tract toxicity for a large number of compounds with diverse chemical structures...
October 16, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29036392/update-from-the-advisory-committee-on-immunization-practices
#16
Sean T O'Leary, David W Kimberlin
The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. The group has 15 voting members, and each member's term is 4 years. ACIP members and Centers for Disease Control and Prevention (CDC) staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. Representatives from the American Academy of Pediatrics (Carrie L...
September 25, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/29035964/medication-safety-programs-in-primary-care-a-scoping-review
#17
Hanan Khalil, Monica Shahid, Libby Roughead
BACKGROUND: Medication safety plays an essential role in all healthcare organizations; improving this area is paramount to quality and safety of any wider healthcare program. While several medication safety programs in the hospital setting have been described and the associated impact on patient safety evaluated, no systematic reviews have described the impact of medication safety programs in the primary care setting. A preliminary search of the literature demonstrated that no systematic reviews, meta-analysis or scoping reviews have reported on medication safety programs in primary care; instead they have focused on specific interventions such as medication reconciliation or computerized physician order entry...
October 2017: JBI Database of Systematic Reviews and Implementation Reports
https://www.readbyqxmd.com/read/29035731/postoperative-adjuvant-sorafenib-or-sunitinib-for-nonmetastatic-renal-cell-carcinoma-with-venous-tumor-thrombus-a-prospective-cohort-study
#18
Liangyou Gu, Hongzhao Li, Luyao Chen, Xintao Li, Baojun Wang, Qingbo Huang, Fan Zhang, Yang Fan, Yu Gao, Cheng Peng, Xin Ma, Xu Zhang
PURPOSE: To evaluate the efficacy and safety of antiangiogenic agents (sorafenib and sunitinib) as postoperative adjuvant therapy in patients with nonmetastatic renal cell carcinoma (RCC) and venous tumor thrombus (VTT). MATERIAL AND METHODS: From March 2006 to January 2016, 147 patients who met the inclusion criteria were enrolled; 27 patients received sorafenib, and 17 patients received sunitinib. After radical nephrectomy and thrombectomy, the duration of maintenance targeted medication treatment was approximately 1 year...
October 13, 2017: Translational Oncology
https://www.readbyqxmd.com/read/29035574/a-6-month-open-label-extension-study-of-vortioxetine-in-pediatric-patients-with-depressive-or-anxiety-disorders
#19
Robert L Findling, Adelaide S Robb, Melissa P DelBello, Michael Huss, Nora K McNamara, Elias H Sarkis, Russell E Scheffer, Lis H Poulsen, Grace Chen, Ole M Lemming, Philippe Auby
OBJECTIVES: In this 6-month open-label extension (OLE) of NCT01491035 (a 14-day, open-label, pharmacokinetic/safety lead-in study), the long-term safety and tolerability of vortioxetine (5-20 mg/day) were investigated in children and adolescents with a DSM-IV-TR™ diagnosis of depressive or anxiety disorder in the United States or Germany. The study also was designed to provide data to inform dose selection and titration in future pediatric studies with vortioxetine. METHODS: Safety evaluations included spontaneously reported adverse events (AEs), the Columbia Suicide Severity Rating Scale (C-SSRS), and the Pediatric Adverse Events Rating Scale (PAERS; clinician administered)...
October 16, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29035427/differences-in-the-korea-acute-myocardial-infarction-registry-compared-with-western-registries
#20
REVIEW
Doo Sun Sim, Myung Ho Jeong
The Korea Acute Myocardial Infarction Registry (KAMIR) is the first nationwide registry that reflects current therapeutic approaches and acute myocardial infarction (AMI) management in Korea. The results of the KAMIR demonstrated different risk factors and responses to medical and interventional treatments. The results indicated that the incidence of ST-elevation myocardial infarction (STEMI) was relatively high, and that the prevalence of dyslipidemia was relatively low with higher triglyceride and lower high-density lipoprotein cholesterol levels...
September 18, 2017: Korean Circulation Journal
keyword
keyword
9024
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"